{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-006959","form_type":"8-K","ticker":"OPRX","cik":"0001448431","company_name":"OptimizeRx Corp","filed_at":"2024-01-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.222427+00:00","generated_at":"2026-06-06T16:30:10.589926+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"OptimizeRx announces Chair retirement; Lynn O'Connor Vos appointed Chair, Catherine Klema added as director","bullets":["Gus Halas retired as Chairperson effective Jan 24, 2024, after nearly a decade of service.","Lynn O'Connor Vos appointed Chairperson, also joins Nominating & Governance, Compensation, and Audit committees.","Board increased to 7 members; Catherine M. Klema appointed as director and member of Audit and Compensation committees.","Klema receives annual cash retainer $40,000, equity grant $150,000, plus additional committee retainers ($10k Audit, $5k Comp)."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-006959","json":"https://secwatch.observer/filing/0001213900-24-006959.json","markdown":"https://secwatch.observer/filing/0001213900-24-006959.md","text":"https://secwatch.observer/filing/0001213900-24-006959.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1448431/000121390024006959/0001213900-24-006959-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1448431/000121390024006959/ea192296-8k_optimizerx.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T16:30:10.589926+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"88b8227f20","claim":"Catherine M. Klema was appointed as Director at OptimizeRx Corp.","evidence_excerpt":"Effective January 24, 2024, the Board increased the size of the Board to seven (7) members and, upon the recommendation of the Board’s Nominating & Governance Committee, appointed Catherine M. Klema to serve as a director of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1448431/000121390024006959/0001213900-24-006959-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"9adccab254","claim":"Lynn O'Connor Vos was appointed as Chairperson of the Board at OptimizeRx Corp.","evidence_excerpt":"Effective January 24, 2024, the Board appointed Lynn O’Connor Vos, a director of the Company, to serve as Chairperson of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1448431/000121390024006959/0001213900-24-006959-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chairperson of the Board"}],"fact_type":"executive_change"},{"claim_id":"fcda3b2d51","claim":"Gus Halas retired as Chairperson of the Board at OptimizeRx Corp.","evidence_excerpt":"Effective January 24, 2024, Gus Halas retired from his position as Chairperson of the Board of Directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1448431/000121390024006959/0001213900-24-006959-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retired"},{"label":"Role","value":"Chairperson of the Board"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}